The hand-held Fourier transform infrared (FTIR) spectroscopy device, developed by Glyconics Ltd., analyses the composition of sputum from patients with chronic obstructive pulmonary disease (COPD), to diagnose and monitor the disease. The device is intended to be used in the home by health professionals, as well as in primary care and hospital outpatient clinics.
Nintedanib is already licensed for treating idiopathic pulmonary fibrosis which is a subtype of ILDs. Nintedanib acts by blocking specific enzymes and pathways that lead to the development of blood vessels within lung cells involved in the scarring process. This inhibits further growth of the scarring tissues resulting in slowing of the disease progression. This action has been shown to be similar in patients with idiopathic pulmonary fibrosis. If licensed, nintedanib may provide the first novel therapy for PF-ILD where limited treatment options currently exist.